Overview
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Status:
Completed
Completed
Trial end date:
2016-04-21
2016-04-21
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Rigel Pharmaceuticals
Criteria
Inclusion Criteria:- Clinical diagnosis of persistent/chronic ITP for at least 3 months.
- Average platelet count < 30,000/µL (and none > 35,000 unless as a result of rescue
therapy) from at least 3 qualifying counts
Exclusion Criteria:
- Clinical diagnosis of autoimmune hemolytic anemia
- Uncontrolled or poorly controlled hypertension
- History of coagulopathy including prothrombotic conditions